Aptamer Nanomaterials for Ovarian Cancer Target Theranostics.

Front Bioeng Biotechnol

Department of Gynecology and Obstetrics, the Second Hospital of Jilin University, Changchun, China.

Published: March 2022

Ovarian cancer is among the leading causes of gynecological cancer-related mortality worldwide. Early and accurate diagnosis and an effective treatment strategy are the two primary means of improving the prognosis of patients with ovarian cancer. The development of targeted nanomaterials provides a potentially efficient strategy for ovarian cancer theranostics. Aptamer nanomaterials have emerged as promising nanoplatforms for accurate ovarian cancer diagnosis by recognizing relevant biomarkers in the serum and/or on the surface of tumor cells, as well as for effective ovarian cancer inhibition target protein blockade on tumor cells and targeted delivery of various therapeutic agents. In this review, we summarize recent advances in aptamer nanomaterials as targeted theranostic platforms for ovarian cancer and discusses the challenges and opportunities for their clinical application. The information presented in this review represents a valuable reference for creation of a new generation of aptamer nanomaterials for use in the precise detection and treatment of ovarian cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996158PMC
http://dx.doi.org/10.3389/fbioe.2022.884405DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
32
aptamer nanomaterials
16
ovarian
8
cancer
8
tumor cells
8
aptamer
4
nanomaterials ovarian
4
cancer target
4
target theranostics
4
theranostics ovarian
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!